Efficacy of recombinant human endostatin combined with TACE on hepatocellular carcinoma

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-17010698

Enrollment

Unknown

Registered

2017-02-21

Start date

2017-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

2:Endostar

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: BCLC stage B or C; Chid - pugh A or B.

Exclusion criteria

Exclusion criteria: Patients with major portal vein/inferior vena cava tumor thrombus

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactHai Lan

Fujian Provincial Cancer Hospital

fjzljr@qq.com+86 13850171973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026